Cellectis S.A. (CLLS) stock
CLLSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.06+0.02 (+1.92%)
Close on Nov 17, 2026Market cap $106.36MP/E –Yield –
Cellectis operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
For fiscal 2025 it was -$39.40M, down 271.4% from the year before. The highest annual figure on record is $22.99M in fiscal 2024.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$39.40M | -271.4% |
| FY2024 | Dec 31, 2024 | $22.99M | – |
| FY2023 | Dec 31, 2023 | -$24.75M | – |
| FY2022 | Dec 31, 2022 | -$87.44M | – |
| FY2021 | Dec 31, 2021 | -$104.56M | – |
| FY2020 | Dec 31, 2020 | -$80.26M | – |
| FY2019 | Dec 31, 2019 | -$69.14M | – |
| FY2018 | Dec 31, 2018 | -$68.14M | – |
| FY2017 | Dec 31, 2017 | -$52.33M | – |
| FY2016 | Dec 31, 2016 | -$32.71M | -1010.9% |
| FY2015 | Dec 31, 2015 | $3.59M | – |
See a number that looks wrong?